Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...
Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of ...
GlobalData on MSN7d
Chugai and Araris enter $780m ADC research collaborationAraris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.
Pharmaceutical Technology on MSN1d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mAdditionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V.
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...
InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and development, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback